Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF-06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects-Reference-Cited by-同舟云学术

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF-06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects

Published:2017-09-07 Issue:5 Volume:7 Page:484-497
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Bhattacharya Indranil¹,Pawlak Sylvester²,Marraffino Shannon³,Christensen Jared¹,Sherlock Sarah P.¹,Alvey Christine⁴,Morris Carl⁵,Arkin Steven²,Binks Michael²

Affiliation:

1. Early Clinical Development; Pfizer Inc.; Cambridge, MA USA

2. Global Product Development; Pfizer Inc.; New Haven, CT USA

3. Rare Disease Research Unit; Pfizer Inc.; Cambridge, MA USA

4. Clinical Pharmacology; Pfizer Inc.; Groton, CT USA

5. Solid Biosciences; Cambridge, MA USA

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Reference16 articles.

1. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member;McPherron;Nature,1997

2. Powerful genes-myostatin regulation of human muscle mass;McNally;N Engl J Med,2004

3. Myostatin mutation associated with gross muscle hypertrophy in a child;Schuelke;N Engl J Med,2004

4. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer;Gordon;J Clin Oncol,2001

5. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis;Rebbapragada;Mol Cell Biol,2003

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Bimagrumab on body composition: a systematic review and meta-analysis;Aging Clinical and Experimental Research;2024-09-09

2. The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy;Neurology and Therapy;2024-01-08

3. Current and investigational medications for the treatment of sarcopenia;Metabolism;2023-12

4. Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies;Pharmacology & Therapeutics;2023-04

5. The elusive role of myostatin signaling for muscle regeneration and maintenance of muscle and bone homeostasis;Osteoporosis and Sarcopenia;2023-03